Short-term Effects Of Cannabinoids On Immune Phenotype And Function In HIV-1-infected Patients
Notes for this study:
|Number of Subjects
In a randomized, double-blind, placebo-controlled trial, participants with HIV-1 infections received placebo, dronabinol, or smoked cannabis for 21 days. The cannabis cigarettes containing 3.95% THC. 62 participants completed the trial.
Lymphocyte count increased more in the cannabis group than placebo by the end of the trial, while there weren't other statistically significant differences for change in naive, memory, or absolute CD4+, CD8+ T cells T cells. Nor was there a significant difference for B cells or Natural Killer cells. There were some statistically significant changes in aspects of NK cell activity between placebo and cannabis.